We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

51 hedge funds and large institutions have $27.9M invested in Theriva Biologics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more capital invested

Capital invested by funds: $20.6M → $27.9M (+$7.27M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

4% less funds holding

Funds holding: 53 → 51 (-2)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
51
Holders Change
-2
Holders Change %
-3.77%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
7
Reduced
7
Closed
9
Calls
$9.75M
Puts
–
Net Calls
+$9.75M
Net Calls Change
+$3.84M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$121K
2
BlackRock
BlackRock
New York
+$116K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$69.4K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$63.6K
5
PPA
Parametric Portfolio Associates
Washington
+$63.6K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.5M
2
William Blair & Company
William Blair & Company
Illinois
-$906K
3
Goldman Sachs
Goldman Sachs
New York
-$639K
4
UOC
UBS O'Connor
Illinois
-$424K
5
PP
Paloma Partners
Connecticut
-$207K
Name Holding Trade Value Shares
Change 		Change in
Stake
TS
1
Third Security
Virginia
$12.4M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.23M +$121K +21 +4%
MP
3
MSD Partners
New York
$3.84M – – –
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$1.64M -$1.5M -260 -56%
BlackRock
5
BlackRock
New York
$1.25M +$116K +20 +15%
Millennium Management
6
Millennium Management
New York
$1.01M -$133K -23 -16%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$474K +$69.4K +12 +26%
EDRH
8
Edmond de Rothschild Holding
Switzerland
$345K – – –
UBS Group
9
UBS Group
Switzerland
$267K +$57.8K +10 +43%
ECM
10
Element Capital Management
New York
$171K -$197K -34 -62%
LTFS
11
Ladenburg Thalmann Financial Services
Florida
$169K +$34.7K +6 +40%
Creative Planning
12
Creative Planning
Kansas
$165K – – –
Northern Trust
13
Northern Trust
Illinois
$161K – – –
IA
14
IFP Advisors
Florida
$153K – – –
SBIA
15
Sheaff Brock Investment Advisors
Indiana
$131K – – –
Fisher Asset Management
16
Fisher Asset Management
Washington
$125K – – –
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$94K – – –
SAM
18
Scopus Asset Management
New York
$93K – – –
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$90K +$63.6K +11 New
VCM
20
Vivaldi Capital Management
Illinois
$89K – – –
PPA
21
Parametric Portfolio Associates
Washington
$86K +$63.6K +11 New
Squarepoint
22
Squarepoint
New York
$85K +$11.6K +2 +25%
VF
23
Virtu Financial
New York
$79K +$57.8K +10 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$68K – – –
BA
25
Bard Associates
Illinois
$62K – – –
1
2 3

TOVX Hedge Fund Activity: Q3 2017 in Review

51 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2017, worth a combined $27.9M — up 35% from $20.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TOVX and 8 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $121K. The largest seller was Alyeska Investment Group, cutting an estimated $1.5M.

  • 51 institutional investors held Theriva Biologics (TOVX) as of Q3 2017, down from 53 in Q2 2017.
  • Funds reported $27.9M of Theriva Biologics stock for Q3 2017, up 35% quarter-over-quarter.
  • 8 funds opened new Theriva Biologics positions in Q3 2017 and 9 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q3 2017 was Vanguard Group, an estimated $121K added.
  • The largest Theriva Biologics seller in Q3 2017 was Alyeska Investment Group, an estimated $1.5M sold.

Based on aggregated 13F filings for Q3 2017.